Selected list of Publications and Patents:
1. J Infect Dis. 211:2015:486 [IF: 6.3]. Triggering through TLR-2 limits chronically stimulated Th1 cells from undergoing exhaustion. Chodisetti SB, Gowthaman U, Rai PK, Vidyarthi A, Khan N, Agrewala JN.
2. J Biol Chem. 289:2014:17515-28 [IF: 4.8]. Caerulomycin A enhances the TGF-β-Smad3 signalling by suppressing IFN-γ-STAT1 signalling to expand Tregs. Gurram RK, Kujur W, Maurya SK, Agrewala JN.
3. J Infect Dis. 209:2014:1436-45 [IF: 6.3]. Latency Associated Protein Acr1 Impairs Dendritic Cells Maturation and Functionality: A Possible Mechanism of Immune Evasion by Mycobacterium tuberculosis. Siddiqui KF, Amir M, Gurram RK, Khan N, Arora A, K Rajagopal, Agrewala JN.
4. Crit Rev Microbiol. 2014 Feb 4. [IF: 6.2]. Challenges and Solutions for a Rational Vaccine Design for TB-endemic Regions, Gowthaman U, Mushtaq K, Tan AC, Rai PK, Jackson DC, Agrewala JN.
5. Crit Rev Microbiol. 40:2014:273-280. [IF: 6.2]. Friendly Pathogens: Prevent or Provoke Autoimmunity. Sathybama S, Khan N, Agrewala JN.
6. J Biol Chem. 288: 2013:29987-99 [IF: 4.8]. Truncated hemoglobin, HbN, is post-translationally modified in Mycobacterium tuberculosis and modulates host-pathogen interactions during intracellular infection. Arya S, Sethi D, Singh S, Hade MD, Singh V, Raju P, Chodisetti SB, Verma D, Varshney GC, Agrewala JN, Dikshit KL.
7. Trends Mol Medicine. 18:2012:607-14. [IF: 11.05]. Lipidated promiscuous peptides vaccine for tuberculosis endemic regions. Gowthaman U, Rai PK, Khan N, Jackson D, Agrewala JN.
8. PLoS Pathogens. 8:2012:e1002676. [IF: 9.23]. Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici. Khan N, Gowthaman U, Pahari S, Agrewala JN.
9. J Immunol. 188:2012:5593. [IF: 5.8]. M. tuberculosis modulates macrophage lipid-sensing nuclear receptors PPARγ and TR4 for survival. Mahajan S, Dkhar KH, Chandra V, Dave S, Nanduri R, Janmeja AK, Agrewala JN, Gupta P.
10. J Infect Dis. 204:2011:1328-38. [IF: 6.3]. Promiscuous peptide of 16 kDa antigen linked to Pam2Cys protects against M. tuberculosis by evoking enduring memory T cells response. Gowthaman U, Singh V, Zeng W, Jain S, Siddiqui KF, Chodisetti SB, Gurram RK, Parihar P, Gupta P, Gupta UD, Jackson DC, Agrewala JN.
11. Crit Rev Microbiol. 37:2011:349-57 [IF: 6.27]. Understanding the biology of 16 kDa antigen of Mycobacterium tuberculosis: scope in diagnosis, vaccine design and therapy. Siddiqui KF, Amir M,Agrewala JN.
12. J Infect Dis. 202:2010:480-9 [IF: 6.3]. Coadministration of IL-7 and IL-15 with BCG mount enduring T cell memory response against M. tuberculosis. Singh V, Gowthaman U, Jain S, Parihar P, Banskar S, Gupta P, Gupta UD, Agrewala JN.
13. J Proteome Res. 7:2008:154-63. [IF: 7.00]. In silico tools for predicting peptides binding to HLA-class II molecules: more confusion than conclusion. Gowthaman U, Agrewala JN.
14. J Biol Chem. 282:2007:6106-15 [IF: 7.1]. Unique ability of activated CD4+ T cells but not rested effectors to migrate to non-lymphoid sites in the absence of inflammation. Agrewala JN, Brown DM, Lepak NM, Duso D, Huston G, Swain SL.
15. Immunol Rev. 211:2006:8-22 [IF: 10.8]. CD4 memory: generation and multi-faceted roles for CD4 T Cells in protective immunity to influenza. Swain SL, Agrewala JN, Brown D, Gibbs DJ, Golech S, Huston G, Jones S, Kamperschroer C, Lee WH, McKinstry K, Roman E, Strutt T, Weng NP.
16. J Infect Dis. 190:2004:107-14 [IF: 6.3]. Potent role of the vaccines prepared from macrophages infected with live bacteria in protection against M. tuberculosis and S. typhimurium infections. Sharma N, Agrewala JN.
17. J Biol Chem. 277:2002:7766-75 [IF: 7.6]. Distinct Role of CD80 and CD86 in the regulation of the activation of B cell and B cell Lymphoma. Suvas S, Singh, V, Sahdev, S, Vohra, H, Agrewala, JN.
18. Eur J Immunol. 29:1999:1753-61 [IF: 5.6]. Influence of HLA-DR on the phenotype of CD4+ T lymphocytes specific for an epitope of the 16-kD α-crystalline antigen of Mycobacterium tuberculosis. Agrewala JN, Wilkinson RJ.
19. J Immunol. 160:1998:1067-77 [IF: 7.2]. Differential effect of anti-B7-1 and anti-M150 antibodies in restricting the delivery of costimulatory signals from B cells and macrophages. Agrewala JN, Suvas S, Verma RK, Mishra GC.
20. Eur J Immunol. 24:1994:2092-7 [IF: 6.0]. A 150-kDa molecule of murine macrophage membrane stimulates interleukin-2 and interferon-g production and proliferation of ovalbumin-specific CD4+ T cells. Agrewala JN, Vinay DS, Joshi A, Mishra GC.
21. J Immunol. 153:1994:1613-25 [IF: 7.4]. Antigen-specific early primary humoral responses modulate Immunodominance of B cell epitopes. Vijayakrishnan L, Kumar V, Agrewala JN, Mishra GC, Rao KVS.
For complete list of publications visit
1. Agrewala JN, Sharma N. Process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infectious diseases and the vaccine produced by the process.  United States Patent No. 6,783,765, South Africa Patent No. 2002/2511, Russian and Bangladesh Patent No. 1003852. European Patent Application No. PCT/IN01/00047.
2. Singla AK, Agrewala JN, Vohra RM, Jolly RS. Caerulomycin A as an immunosuppressive agent. United States Patent No. 8,114,895 on February 14, 2012.
3. Agrewala JN, Gowthaman U, Jackson D, Zeng W. Targeting promiscuous peptides to dendritic cells for generating long-lasting immunity and development of vaccines [Patent application No. 13/822881, Sep 14, 2011].
4. Sarkar D, Samuel JS, Agrewala JN, SB Chodsetti. Erythropoietin variants with increased protease resistance (patent filed: 2013).
1. Management of infectious Diseases by immunomodulation [No. OLP-088]. Funding agency: Council of Scientific and Industrial Research, India.
2. Novel vaccine delivery systems that elicit robust and enduring T cell memory responses: alternatives to BCG vaccination in tuberculosis endemic regions [No. GAP-103]. Funding agency: Department of Biotechnology, India.